BioSpace News Archive

Envista Holdings Corporation will report financial results for its second quarter 2023 on Wednesday, August 2, 2023.

AbCellera will announce its second quarter 2023 financial results on Thursday, August 3, 2023, and hold an earnings conference call at 2:00 p.m. Pacific Time the same day.

AcariaHealth, the fifth largest specialty pharmacy in the U.S., announced that it has been selected by Sarepta Therapeutics, Inc. as part of the limited distribution network for ELEVIDYS.

Sequana Medical NV announces that it has implanted the 1,000thalfapump for the treatment of recurrent and refractory ascites due to liver cirrhosis and malignant ascites.

Astellas Pharma Inc. announced that the U.S. Food and Drug Administration has accepted and granted Priority Review for the company’s Biologics License Application for zolbetuximab, a first-in-class investigational Claudin 18.2 -targeted monoclonal antibody, for first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma whose tumors are CLDN18.2-positive.

Hansa Biopharma AB will publish its interim report for January-June 2023 at 8:00 CET on July 20, 2023.

Extendicare Inc. announced that it plans to release its financial results for the second quarter of 2023 after market close on Thursday, August 10, 2023.

Metrion Biosciences Limited announced the appointments of Dr Robert Kirby to Chief Operating Officer and Dr Edward Stevens to Chief Scientific Officer.

Osivax announced the publication of promising preclinical proof of cross-protection data against multiple SARS-CoV-2 variants with OVX033, its sarbecovirus vaccine candidate, in a hamster challenge model.

Biogen Canada Inc. is pleased to announce that Quebec has become the first province to reimburse Pr BYOOVIZ™ (ranibizumab injection), an anti-vascular endothelial growth factor (anti-VEGF) biosimilar therapy for certain eye conditions affecting the retina.